Institutional members access full text with Ovid®

Population demographics and socioeconomic impact of osteoporotic fractures in Canada

Lorrain, Jacques MD1,2; Paiement, Guy MD3; Chevrier, Normand4; Lalumière, Gaston PhD1,6; Laflamme, Georges-Henri MD, FRCS(C), MSc1,6; Caron, Pierre MD1; Fillion, Anne MSc1,5


Through a survey of the literature and an analysis of selected national and regional statistics, a review of the incidence of osteoporosis and its consequences was performed. Results illustrate that the consequences of osteoporosis are preventable and should sensitize clinicians to the importance of early detection and the identification of risk factors for disease prevention and to early treatment once disease has been established. A marked increase in the annual incidence of hip fractures in all Canadians is noted. Whereas the incidence was less than 20,000 in 1981, the incidence of hip fracture grew to 27,342 in 1995, with 73% occurring in women. It is estimated that in Canada at least one in four women older than 50 years will have one or more osteoporosis-related fractures in their lifetimes. The consequences of these fractures are considerable, both for patients and healthcare services. Only half of all victims regain total autonomy, and the total direct costs in Canada stemming from osteoporosis are estimated to be $1.3 billion per year.

Osteoporosis is a systemic disease characterized by bone mass deficiency and deterioration of the bone's microarchitecture. Consequently, bone that is fragile by nature has increased susceptibility to fractures. 1 Osteoporosis has serious physical, psychosocial, and financial consequences, placing a significant burden on individuals, on the families of those affected, and on society. Fractures related to osteoporosis often entail a number of serious complications, which in turn lead to enormous expense and often death.

From the 1Hôpital du Sacré-Cœur de Montréal, Montreal, Canada, 2Département d'obstétrique-gynécologie, Université de Montréal, Montreal, Canada, 3University of California, San Francisco, California, 4Aymes Medical, Aurora, Ontario, Canada, 5Faculté de Pharmacie, Université de Montréal, Montreal, Canada, 6Faculté de Médecine, Université de Montréal, Montreal, Canada.

Received March 29, 2002; revised and accepted September 26, 2002.

This work was supported by an unrestricted educational grant from Merck Frosst Canada.

Address reprint requests to Jacques Lorrain, MD, Clinique d'ostéoporose, Hôpital du Sacré-Cœur de Montréal, 5400, boul. Gouin Ouest, Montréal (Québec), Canada, H4J 1C5.

©2003The North American Menopause Society